

Curriculum Vitae
Marc A. Darst, MD

Current Practice:

Darst Dermatology, PC
11301 Golf Links Drive North, Suite 203
Charlotte, NC 28277
704-321-3376

Dermatopathologist
Charlotte Dermatopathology, LLC
11301 Golf Links Drive North
Charlotte, NC 28277
704-321-3376

Site Affiliation:

2015-Present
DJL Clinical Research, PLLC
431 N Wendover Rd
Charlotte, NC 28211

Medical Licensure:

2007-present
2008-present
State of North Carolina Medical License
State of South Carolina Medical License

Education:

2007
University of Texas Southwestern
Dermatopathology Fellowship
Cockerell and Associates
Dallas, Texas

2006
Wright State University School of Medicine
Dermatology Residency Program
Dayton, Ohio

1993
Community Hospitals of Indianapolis
Family Practice Residency Program
Indianapolis, Indiana

1990
MD, Indiana University
Indianapolis, Indiana

1986
BA, Mathematics, Magna cum Laude
DePauw University
Greencastle, Indiana

Certifications:

2008-2018
2006-2026
1999-2006
1993-2000
American Boards of Dermatology and Pathology (Dermatopathology)
American Board of Dermatology
American Board of Family Medicine (recertified)
American Board of Family Medicine

Curriculum Vitae
Marc A. Darst, MD

Professional Experience:

2008-Present	MD/Owner Darst Dermatology, PC Charlotte, NC
2007-2008	Assistant Professor of Dermatology Wright State University Boonschoft School of Medicine Dayton, Ohio
2007-2008	Dermatopathologist Dermatopathology Laboratory of Central States Dayton, Ohio
2002-2003	Emergency Physician St. Vincent Mercy Hospital Elwood, Indiana
2001-2002	Clinical Research Fellow Indiana University School of Medicine Department of Dermatology Indianapolis, Indiana
1996-2001	Family Physician Oaklandon Family Medicine Indianapolis, Indiana
1993—1996	Family Physician Office of Family Medicine Portland, Indiana

Meetings:

Faculty, 2016 DASIL Annual Meeting, Dubai, UAE

Faculty, 2010, 2011, 2012, 2013, 2014, 2015, 2016 cosmetic Surgery Forum, Las Vegas, NV

Faculty, 2007 Skin Curriculum Overview for Physician Extenders, Dallas, TX

Assistant Faculty, Basic Dermatopathology Self-Assessment Course.
Washington DC, 2007 American Academy of Dermatology Annual Meeting

Chairman, American Academy of Dermatology Practice Management Symposium
Workgroup for 2005 AAD Annual Meeting

Service:

2018-2020	Speaker: Galderma Pharmaceuticals
2016-Present	Chairman, Electronic Health Record Task Force, American Academy of Dermatology
2012-present	Board of Directors, Independent Physicians of the Carolinas, Charlotte, NC
2012	President, Charlotte Dermatologic Society, Charlotte, NC
2012-2013	Sponsor, AAD Shade Structure Grant Program, Marvin Ridge Elementary School
2012-2013	Sponsor, AAD Shade Structure Grant Program, Sandy Ridge Elementary School
2011, 2012	Sponsor, Senior Honors Dinner and Awards Program, Cuthbertson High School
2011-present	Darst Dermatology Scholarship, Weddington High School

Curriculum Vitae
Marc A. Darst, MD

2006	Founding Board of Directors, Crimestoppers of Jay County, Indiana
2005-2006	Residency Review Preparation Committee, Wright State University
2003-2006	Facilities Committee, Carillon Historical Park Society, Dayton, OH
2000-2003	Alternate Delegate to Indiana State Medical Association Convention
1999-2000	Board of Governors, Indianapolis Metropolitan YMCA
1997-2001	Clinical Instructor, Community Hospitals of Indianapolis Family Medicine (Residency)
1994-1996	Rotary Club of Jay County, Indiana
1993-2001	Clinical Assistant Professor, Indiana University School of Medicine
1993-1996	Medical Director of Respiratory Services, Jay County Hospital
1991-1993	Neonatal Resuscitation Review Committee, Community Hospital, Indianapolis
1982-2002	Board of Directors, Fort Harrison YMCA
1983-1985	DePauw University Humanitarian Missions
	-1983 L'Acul Haiti. Constructed medical clinic in rural Haiti
	-1984 Azpitia Peru. Assisted physician and dental teams in rural Peru
	-1985 Puno, Peru. Student Leader of physician team in rural Peru

Associations:

Fellow, American Academy of Dermatology
Fellow, American Academy of Family Practice
American Society of Dermatopathology
American Society for Dermatologic Surgery
North Carolina Dermatological Association

Publications:

Darst M, Donnelly H. S-plasty repair of lesions involving the dorsum and lateral side wall of the nose. Submitted for publication to Dermatologic Surgery.

Darst M, Blankenship C. Pharmacoeconomics (Chapter 46) in Wolverton SE (ed.) Comprehensive Dermatologic Drug Therapy. Philadelphia, WB Saunders, 2001.

Nomura I, Gao B, Boguniewicz M, **Darst MA**, Travers JB, Leung DY. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: A gene microarray analysis. J Allergy Clin Immunol. 2003 Dec; 112(6):1195-202

Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, **Darst MA**, Gao B, Boguniewicz M, Travers JB, Leung DY. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003 Sep 15; 171(6):3262-9

Wolverton SE, **Darst M**. Other Systemic Drugs (Chapter 131) in Bologna J, et al (eds.) Dermatology. London, Mosby (Elsevier), 2003.

Darst M, Al-Hassani M, Li T, Yi Q, Travers JM, Lewis DA, Travers JB. Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma line. J Immunol. 2004 May 15; 172(10):6330-5.

Wolverton SE, **Darst M**. Other Systemic Drugs (Chapter 130) in Bologna J, et al (eds.) Dermatology. London, Mosby (Elsevier), 2007.

Kerns MJ, Moad J, **Darst MA**. Scalp Melanoma in a 9-Year-Old Boy. Pathol Case Rev. 2007 Nov/Dec; 12(6):254-257.

Curriculum Vitae
Marc A. Darst, MD

Davis LE, Farley EA, **Darst MA**, Thomas D, Cockerell CJ. Calciphylaxis in patients with POEMS syndrome. Accepted for publication. *AM J Dermatopathology*. 2007

Kerns MJ, **Darst MA**, Olsen TG, Grevey S, Hall P, Fenster M. Shrinkage of cutaneous specimens: formalin or other factors involved? Accepted for Publication. *J Cut Path*. 2007

Darst M, Reddan H. Pharmacoeconomics (Chapter 56) in Wolverton SE (ed.) *Comprehensive Dermatologic Drug Therapy*, 2nd Ed. Elsevier Press, London, 2007

Darst M. Advocacy Success: CMS Final Rule Shortens Reporting Period for MU. *American Academy of Dermatology*. December 2016.

Ichiro Nomura, Elena Goleva, Michael D. Howell, Quatyba A. Hamid, Peck Y. Ong, Clifton F. Hall, **Marc A. Darst**, Bifeng Gao, Mark Boguniewicz, Jeffrey B. Travers, and Donald Y. M. Leung. Cytokine Milieu of Atopic Dermatitis, as Compared to Psoriasis, Skin Prevents Induction of Innate Immune Response Genes. *The Journal of Immunology*.

Presentations:

Darst MA, Roberts RA, Detweiler JG, Cockerell CJ. Orofacial Granulomatosis secondary to cinnamaldehyde exposure. Poster at American Society of Dermatopathology Annual Meeting, Chicago IL. October 2006.

Darst MA, Kerns MH, Heffernan M. Determination of tissue shrinkage post excision and in formalin. Poster at American Society of Dermatopathology Annual Meeting, Chicago IL. October 2006.

Darst M, Heffernan M. Recognizing Common cutaneous Malignancies. Lecture to Internal Medicine Resident Educational Conference, Wright State University School of Medicine, Internal Medicine Residency Program. May 2006

Rashid B, **Darst M**, Verma S, Heffernan M. Paraneoplastic Pemphigus and the Sign of Leser-Trélat, a novel presentation. Poster Presentation, 7th annual Dayton Area Graduate Medical Education Consortium (DAGMEC) Resident Research Forum, April 2006.

Darst M. Sun Safety. Presentation to 5th Grade convocation at JF Kennedy Elementary Scholl, Kettering, Ohio. Part of Skin Cancer Prevention Week. May 2005.

Heaphy M, **Darst M**. Sun Safety. Presentation to 5th Grade convocations at Oakview Elementary School and JF Kennedy Elementary School, Kettering, Ohio. Part of Skin Cancer Prevention Week. May 2004.

Darst M, Al-Hassani M, Li t, Yi Q, Travers JM, and Travers JB. Augmentation of Chemotherapy-induced Cytokine Production by Expression of the Platelet-activating Factor Receptor in a Human Epithelial Carcinoma Cell Line. Poster presented at International Investigative Dermatology 2003 Annual Meeting.

Draft KS, **Darst MA**, Southall MD, Travers JB. Systemic exposure to the inflammatory lipid mediator platelet-activating factor results in immunosuppression in mice. Poster presented at International Investigative Dermatology 2003 Annual Meeting.

Darst M, Guenther S, Lewis C. Wegener's Granulomatosis presenting as Acne Fulminans, Gross and Microscopic presentation. *American Academy of Dermatology annual Meeting* 2002.

Curriculum Vitae
Marc A. Darst, MD

Clinical Research:

Sub-Investigator: Eli Lilly - A multicenter, randomized, double-blind, placebo-controlled 24-week study followed by long-term evaluation of efficacy and safety of Ixekizumab (LY2439821) in biologic disease-modifying antirheumatic drug-experienced patients with active psoriatic arthritis. (2015)

Sub-Investigator: Coherus Biosciences - A double-blind, randomized, parallel-group, active-control study to compare the efficacy and safety of CHS-1420 drug product versus Humira in subjects with chronic plaque psoriasis. (2015)

Sub-Investigator: Boehringer Ingelheim - BI 655066 versus placebo in a Multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment. (2016)

Principal Investigator: Abbvie - A multicenter, open Label study to assess the safety and efficacy of risankizuMab for MalnTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS) (2017)

Principal Investigator – Foamix - A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris. (2017)

Principal Investigator – Cutanea Life Sciences - A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)

Principal Investigator – Vanda Pharmaceuticals Inc- A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (2019)

Principal Investigator – Chemocentryx Protocol - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

Principal Investigator – Skintech - A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

Principal Investigator – Trevi Therapeutics: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) 2019

Principal Investigator – Abbvie: A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis. 2019

Principal Investigator – Vanda Pharmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (3102). 2019

Principal Investigator – Astrazeneca: A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Principal Investigator – Concert Pharmaceuticals: A Double-blind, Randomized, Placebo-controlled study to evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Curriculum Vitae
Marc A. Darst, MD

Principal Investigator – Concert: A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Principal Investigator – Concert: A Multicenter, Open-label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata


Principal Investigator – Abbvie: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects with Moderate to Severe Psoriasis.

Principal Investigator – Janssen: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

My signature verifies the information in this document is accurate and updated appropriately.



Signature



Date